SIBO and Ehlers-Danlos Syndrome: How All 13 EDS Types Affect Your Gut

Ehlers-Danlos Syndrome is not one condition -- it is a family of 13 recognized subtypes, each involving a different defect in collagen or collagen-processing genes. While hypermobile EDS (hEDS) gets most of the attention in SIBO discussions, the reality is that every EDS subtype affects the gastrointestinal tract to some degree, because every layer of the gut wall depends on collagen for structural integrity. Classical EDS patients develop fragile mucosal linings. Vascular EDS patients face life-threatening bowel perforations. Kyphoscoliotic EDS patients deal with severe abdominal wall laxity that distorts organ positioning. Even the rarer subtypes -- spondylodysplastic, musculocontractural, dermatosparaxis -- involve collagen disruptions that impair the gut's ability to move food forward, maintain barrier function, and resist bacterial overgrowth. This article goes beyond hypermobility to examine how the full spectrum of EDS affects SIBO risk, why GI symptoms are so universal across subtypes, and what treatment strategies work when your gut is structurally compromised at the collagen level. If you have any form of EDS and chronic digestive problems, understanding the mechanism behind your symptoms changes everything about how you approach treatment.

The 13 EDS Subtypes and Their GI Impact

The 2017 international classification recognizes 13 EDS subtypes, each caused by mutations in different genes that affect collagen structure, synthesis, or processing. While hEDS is the most common (estimated at 1 in 500 to 1 in 5,000 depending on diagnostic criteria), the other subtypes collectively affect a significant number of patients. Classical EDS (cEDS) involves mutations in COL5A1 or COL5A2 affecting type V collagen, leading to skin hyperextensibility and tissue fragility that extends to the GI mucosa. Vascular EDS (vEDS) is caused by mutations in COL3A1 affecting type III collagen -- the dominant collagen in blood vessels and hollow organs including the intestines -- making it the most dangerous subtype for GI complications including spontaneous bowel perforation. Kyphoscoliotic EDS (kEDS) involves PLOD1 or FKBP14 mutations that impair collagen cross-linking, leading to profound muscle hypotonia that directly weakens the abdominal and intestinal musculature. Classical-like EDS (clEDS), cardiac-valvular EDS, arthrochalasia EDS, dermatosparaxis EDS, spondylodysplastic EDS, musculocontractural EDS, myopathic EDS, periodontal EDS, and brittle cornea syndrome each carry their own collagen defect, and nearly all report GI symptoms at rates far exceeding the general population. The common thread is that defective collagen weakens the structural scaffolding the gut depends on for normal motility.

Why Collagen Defects Lead to SIBO

The gastrointestinal tract is essentially a muscular tube wrapped in connective tissue, and collagen is the primary structural protein holding it all together. The gut wall has four layers: the mucosa (inner lining), submucosa (connective tissue support), muscularis externa (the muscle layers responsible for peristalsis), and serosa (outer covering). Collagen is present in every single layer. In the submucosa, it provides the scaffold that maintains the tube's shape and flexibility. In the muscularis, it forms the extracellular matrix that muscle cells anchor to -- without a strong matrix, muscles cannot generate effective contractile force even if the muscle cells themselves are healthy. In the serosa, it holds the intestines in their proper anatomical position. When collagen is defective, the entire system weakens. Peristalsis becomes sluggish because muscle layers lack structural support. The ileocecal valve -- which depends on connective tissue tension to maintain closure -- becomes incompetent, allowing colonic bacteria to backflow into the small intestine. Organs shift position (visceroptosis), kinking or stretching the intestinal tube in ways that create functional obstructions. The migrating motor complex, which depends on coordinated muscular contractions to sweep bacteria out of the small intestine between meals, cannot generate sufficient force. The result is a small intestine that cannot clear bacteria effectively, creating the perfect environment for SIBO to develop and persist.

Vascular EDS: The High-Stakes GI Subtype

Vascular EDS deserves special attention because it carries unique and serious GI risks that affect how SIBO can be investigated and treated. Type III collagen -- the collagen defective in vEDS -- is the primary collagen in the walls of hollow organs and blood vessels. This means the intestinal wall in vEDS patients is not just lax but genuinely fragile, with a documented risk of spontaneous bowel perforation that affects approximately 25% of vEDS patients over their lifetime. Sigmoid colon perforation is the most common presentation, but small bowel perforations occur as well. This fragility has direct implications for SIBO management: invasive procedures like colonoscopy carry elevated perforation risk and should be approached with extreme caution. Endoscopic biopsies may be contraindicated. Even vigorous abdominal massage or visceral manipulation -- techniques sometimes recommended for SIBO patients -- can be dangerous in vEDS. Breath testing becomes the preferred diagnostic method because it is completely non-invasive. Treatment must prioritize gentle approaches: dietary modifications, carefully dosed antimicrobials, and prokinetics that do not produce aggressive intestinal contractions. Stimulant laxatives should be avoided. Any acute abdominal pain in a vEDS patient should be treated as a potential surgical emergency until proven otherwise, regardless of whether they have an active SIBO diagnosis.

Beyond Hypermobility: GI Symptoms Across EDS Subtypes

Diagnosing SIBO When You Have EDS

SIBO diagnosis in EDS patients follows the same general approach as in the general population -- lactulose or glucose breath testing remains the standard -- but there are important nuances. First, the transit time through the small intestine may be significantly slower in EDS due to dysmotility, which affects the timing of breath test peaks. A delayed rise in hydrogen or methane does not necessarily mean the substrate has reached the colon; it may mean slow small intestinal transit is delaying fermentation. Discuss this with your practitioner when interpreting results. Second, EDS patients frequently have hydrogen sulfide-dominant SIBO, which standard two-gas breath tests do not detect. If your hydrogen and methane breath test is negative but you have classic SIBO symptoms (bloating, pain, diarrhea or constipation, food intolerances), request a three-gas test that measures hydrogen sulfide or consider a trial of treatment. Third, many EDS patients have overlapping conditions -- gastroparesis, visceroptosis, mast cell activation -- that produce symptoms similar to SIBO. A positive breath test confirms SIBO, but a negative test does not rule out other GI pathology that needs attention. Consider GI motility testing (wireless motility capsule or antroduodenal manometry) to evaluate the degree of motility impairment, which directly informs treatment intensity.

Treatment Strategies Across EDS Subtypes

Treating SIBO in EDS requires a subtype-aware approach. For hEDS, the strategy focuses on prokinetics (prucalopride is first-line), mast cell stabilization, autonomic support, and cyclical antimicrobials with the understanding that relapse is likely and maintenance therapy is usually needed long-term. For classical EDS, the approach is similar but with added attention to mucosal healing -- the fragile gut lining benefits from mucosal support supplements like L-glutamine, zinc carnosine, and demulcent herbs. Hernia management may be necessary if hiatal or inguinal hernias are contributing to symptoms. For vascular EDS, as discussed above, treatment must prioritize safety: no invasive procedures, no aggressive mechanical therapies, gentle prokinetics only, and close monitoring for any signs of bowel compromise. For kyphoscoliotic EDS, the severe hypotonia means prokinetics may be less effective because the muscle itself cannot respond adequately, so dietary strategies (smaller meals, low-residue foods, liquid nutrition) become more important. Across all subtypes, the shared principles are: support motility to whatever degree possible, use antimicrobials judiciously, address nutritional deficiencies aggressively, manage comorbidities (autonomic dysfunction, mast cell activation, pain), and plan for long-term management rather than one-time eradication.

Nutritional Priorities for EDS Patients with SIBO

EDS patients with SIBO face a compounding nutritional challenge: the connective tissue disorder increases demand for collagen-building nutrients (vitamin C, zinc, copper, amino acids like proline and glycine), while SIBO impairs absorption of those very nutrients through mucosal inflammation and bacterial competition. Vitamin B12 deficiency is particularly common because bacteria in the small intestine consume B12 before it can be absorbed. Iron deficiency develops from chronic mucosal inflammation. Fat-soluble vitamin deficiencies (A, D, E, K) occur when SIBO damages bile acid metabolism. Magnesium depletion -- already common in EDS due to autonomic dysfunction and medication side effects -- worsens with SIBO-related malabsorption. The priority is to identify and correct deficiencies through testing (serum B12, ferritin, vitamin D, RBC magnesium at minimum), supplement in bioavailable forms that bypass the damaged gut when possible (sublingual B12, transdermal magnesium, liquid vitamin D), and avoid overly restrictive SIBO diets that further limit nutrient intake. Collagen peptide supplementation is commonly used by EDS patients and appears to be well-tolerated even during active SIBO, though evidence for its effectiveness in improving connective tissue integrity is still limited.

Building a Care Team That Understands EDS and SIBO

One of the biggest challenges for EDS patients with SIBO is finding practitioners who understand both conditions. Gastroenterologists typically know SIBO but not EDS. Geneticists diagnose EDS but rarely manage GI complications. The result is patients bouncing between specialists who each address one piece of the puzzle. The ideal team includes a geneticist or rheumatologist for EDS subtype diagnosis and systemic management, a gastroenterologist willing to learn about EDS-specific GI complications (or who already has EDS patients in their practice), a functional or integrative medicine practitioner experienced with SIBO treatment protocols, and a dietitian who understands both the SIBO dietary restrictions and the nutritional demands of EDS. Online EDS communities and the Ehlers-Danlos Society maintain provider directories that can help locate knowledgeable practitioners. Telehealth has expanded access significantly, especially for SIBO management which relies heavily on breath testing and symptom tracking rather than in-person procedures. Using GLP1Gut to track your symptoms, food triggers, and treatment responses gives any practitioner -- even one less familiar with EDS -- concrete data to work with.